TY - JOUR A1 - Godard, A. A1 - Kalot, G. A1 - Privat, M. A1 - Bendellaa, M. A1 - Busser, B. A1 - Wegner, Karl David A1 - Denat, F. A1 - Le Guevel, X. A1 - Coll, J.-L. A1 - Paul, C. A1 - Bodio, E. A1 - Goze, C. A1 - Sancey, L. T1 - NIR-II Aza-BODIPY Dyes Bioconjugated to Monoclonal Antibody Trastuzumab for Selective Imaging of HER2-Positive Ovarian Cancer N2 - Using fluorescence-guided surgery (FGS) to cytoreductive surgery helps achieving complete resection of microscopic ovarian tumors. The use of visible and NIR-I fluorophores has led to beneficial results in clinical trials; however, involving NIR-II dyes seems to outperform those benefits due to the deeper tissue imaging and higher signal/noise ratio attained within the NIR-II optical window. In this context, we developed NIR-II emitting dyes targeting human epidermal growth factor receptor 2 (HER2)-positive ovarian tumors by coupling water-soluble NIR-II aza-BODIPY dyes to the FDA-approved anti-HER2 antibody, namely, trastuzumab. These bioconjugated NIR-II-emitting dyes displayed a prolonged stability in serum and a maintained affinity toward HER2 in vitro. We obtained selective targeting of HER2 positive tumors (SKOV-3) in vivo, with a favorable tumor accumulation. We demonstrated the fluorescence properties and the specific HER2 binding of the bioconjugated dyes in vivo and thus their potential for NIR-II FGS in the cancer setting. KW - NIR-II KW - Fluorescent dye KW - In vivo imaging KW - Ovarian cancer KW - Antibody conjuagtes KW - Bioimaging PY - 2023 DO - https://doi.org/10.1021/acs.jmedchem.3c00100 SN - 0022-2623 VL - 66 IS - 7 SP - 5185 EP - 5195 PB - ACS Publications AN - OPUS4-57293 LA - eng AD - Bundesanstalt fuer Materialforschung und -pruefung (BAM), Berlin, Germany ER - TY - JOUR A1 - Mohammad, W. A1 - Wegner, Karl David A1 - Comby-Zerbino, C. A1 - Trouillet, V. A1 - Ogayer, M. P. A1 - Coll, J.-L. A1 - Marin, R. A1 - Jaque Garcia, D. A1 - Resch-Genger, Ute A1 - Antoine, R. A1 - Le Guevel, X. T1 - Enhanced brightness of ultra-small gold nanoparticles in the second biological window through thiol ligand shell control N2 - Gold-based nanoparticles below 2 nm in size are promising as luminescent probes for in vivo bioimaging, owing to their brightness and rapid renal clearance. However, their use as contrast agents in the near-infrared II (NIR-II, 1000–1700 nm) range remains challenging due to their low photoluminescence (PL) quantum yield. To address this, PL enhancement can be achieved by either rigidifying the ligand-shell structure or increasing the size of the ligand shell. In this study, we synthesized ultra-small gold nanoparticles stabilized by co-ligands, namely monothiol and short dithiol molecules. By precisely controlling the amount of reducing agent used during particle preparation, we successfully modulated the physicochemical properties of the co-ligand shell, including its size, composition, and structure. Consequently, we achieved a remarkable 60-fold increase in the absorption cross-section at 990 nm while maintaining the small size of the 1.5-nm metal core. The analytical and optical characterization of our thiol-capped gold nanoparticles indicates that the ligand shell size is governed by the quantity of the reducing agent, which, in turn, impacts the balance between radiative and non-radiative processes, thereby influencing the PL quantum yield. KW - Gold nanocluster KW - NIR-II fluorescence KW - SWIR KW - Nanomaterial design KW - Calibrated fluorescence measurements PY - 2023 UR - https://nbn-resolving.org/urn:nbn:de:kobv:b43-588117 DO - https://doi.org/10.1039/D3TC03021K SN - 2050-7526 VL - 11 IS - 42 SP - 14714 EP - 14724 PB - Royal Society of Chemistry (RSC) AN - OPUS4-58811 LA - eng AD - Bundesanstalt fuer Materialforschung und -pruefung (BAM), Berlin, Germany ER -